secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001193125-23-046815
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma to merge with Infinity Pharmaceuticals in stock-for-stock deal
-------------------------------------------------------------------------

- MEI Pharma to acquire Infinity via merger; Infinity stockholders receive 1.0449 MEI shares per share.
- Combined company ownership: ~58% MEI stockholders, ~42% Infinity stockholders.
- Closing expected mid-2023; termination fees of $4M (MEI) or $2.9M (Infinity) under certain conditions.
- CEO Daniel Gold to resign; David Urso appointed CEO. Infinity's CMO and CSO to join combined company.
- Board changes: three MEI directors resign; Norman Selby, Adelene Perkins, Richard Gaynor appointed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000119312523046815/0001193125-23-046815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000119312523046815/d428092d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-046815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer